SPHL vs IVF

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 23, 2026

SPHL

32.5
AI Score
VS
IVF Wins

IVF

48.3
AI Score

Investment Advisor Scores

SPHL

33score
Recommendation
AVOID NEW MONEY

IVF

48score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric SPHL IVF Winner
Forward P/E 0 0 Tie
PEG Ratio 0 0 Tie
Revenue Growth 38.4% 16.7% SPHL
Earnings Growth -6.9% 0.0% IVF
Tradestie Score 32.5/100 48.3/100 IVF
Profit Margin -23.4% -92.3% SPHL
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY HOLD IVF

Relative Price Performance (Last 90 Days)

SPHL 1M: -22.7% · 3M: -6.6% IVF 1M: -38.4% · 3M: -39.5%

Current Technical Phase

SPHL

Distribution
Trim / tighten stop

Price near a flattening SMA50 (slope -2.7%) with fading momentum, RSI 48

RSI (14): 48.3 · Price: $2.42

IVF

Markdown
Sell / avoid

Price below a falling SMA50 (slope -11.4%), weak momentum, RSI 30

RSI (14): 29.6 · Price: $0.58

Fundamentals Snapshot

Metric SPHL IVF
Market Cap — —
Forward P/E 0.0 -0.1
Trailing P/E — 0.0
Revenue (TTM) — —
Revenue Growth 0.4% 0.2%
Gross Margin 0.2% 0.4%
Operating Margin -0.1% -0.6%
EPS -0.06 127.95
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, IVF is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.